XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ 5,779,663 $ (9,245,295)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Stock-based compensation 161,710 47,115
Depreciation and amortization 574,002 675,544
Loss on disposal of fixed assets 0 13,988
Interest added to convertible note payable 35,265 344,991
Interest expense for reduction in convertible note conversion price 0 3,488,851
Defined benefit plan obligation 0 (48,377)
Amortization of debt discount and warrant modification 0 384,000
Fair Value Adjustment of Warrants (8,506,000) (0)
Loss on debt extinguishment 125,242 0
Changes in operating assets and liabilities:    
Accounts receivable, net (903,472) 487,262
Inventories, net (384,090) 347,817
Prepaid expenses and other assets 454,235 180,109
Accounts payable (1,657,616) 69,795
Accrued expenses and other liabilities 335,852 381,097
Contract liabilities (54,476) (295,327)
Other 0 185,000
Net cash used in operating activities (4,039,685) (2,983,430)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (23,882) (34,692)
Capitalization of internal use software costs 0 (58,303)
Net cash used in investing activities (23,882) (92,995)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from the sale of Series F preferred stock and warrants 4,500,000 3,025,000
Payment to convertible note 0 (484,950)
Proceeds (repayments) on other short-term loans (135,000) 738,000
Issuance costs for sale of Series F preferred stock and warrants (47,000) (272,976)
Net cash provided by financing activities 5,945,746 3,289,258
Effects of foreign exchange rates on cash flows 6,409 (54,649)
Net change in cash 1,888,588 158,184
Cash at beginning of period 3,613,996 819,024
Cash at end of period 5,502,584 977,208
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Interest cash paid 35,265 468,141
Income taxes paid 0 0
NON-CASH OPERATING AND FINANCING ACTIVITIES:    
Issuance of vested restricted Common Stock 79 1
Amended Series B warrants reclassified to stockholders' equity 7,766,000 0
Conversion of Promissory Note and accrued interest to shares of Common Stock 1,416,995 100,000
Accrued dividends on Series F Preferred Stock 119,688 110,983
Deemed dividends on Series F Preferred Stock, Series B and F Warrants and warrant exchange 4,734,143 5,257,455
Accrued expense settled with Series B Warrant exercise 350,000 0
Conversion of Series F Preferred Stock into Common Stock [Member]    
NON-CASH OPERATING AND FINANCING ACTIVITIES:    
Conversion of Preferred Stock Series F to Common Stock 8,273 117
Series F Warrants exchanged for shares of Common Stock 8,273 117
Conversion of Series F Warrants to Common Stock [Member]    
NON-CASH OPERATING AND FINANCING ACTIVITIES:    
Conversion of Preferred Stock Series F to Common Stock 89 0
Series F Warrants exchanged for shares of Common Stock 89 0
COVID Loan [Member]    
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayments on COVID loans (162,770) (213,517)
Series B Warrants [Member]    
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 1,790,516 0
NON-CASH OPERATING AND FINANCING ACTIVITIES:    
Amended Series B warrants reclassified to stockholders' equity 7,766,000  
Accrued expense settled with Series B Warrant exercise 350,000  
Series F Warrants [Member]    
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants $ 0 497,701
NON-CASH OPERATING AND FINANCING ACTIVITIES:    
Deemed dividends on Series F Preferred Stock, Series B and F Warrants and warrant exchange   $ 5,249,704